Lack of association in Japanese patients between neuroleptic malignant syndrome and the TaqI A polymorphism of the dopamine D2 receptor gene.
OBJECTIVE
The molecular basis of neuroleptic malignant syndrome (NMS) is unclear, but clinical studies have noted a genetic predisposition. A recent genetic study suggested an association between NMS and the I A polymorphism in the dopamine D2 receptor (DRD2 ) gene. We further examined the association in a larger number of subjects.


METHODS
We studied 49 Japanese patients previously diagnosed with NMS, and 123 schizophrenic patients treated with neuroleptics without occurrence of NMS. PCR and RFLP analyses were performed to screen the I A polymorphism.


RESULTS
The I A1 allele frequency was 0.408 in NMS patients and 0.415 in patients without NMS. No significant differences in allelic or genotypic frequencies were observed between the two groups.


CONCLUSIONS
We cannot conclude that the I A polymorphism is associated with development of NMS.
Kishida
Ikuko
I
Department of Psychiatry, Yokohama City University School of Medicine, Yokohama, Japan.
Kawanishi
Chiaki
C
Furuno
Taku
T
Matsumura
Takehiko
T
Hasegawa
Hana
H
Sugiyama
Naoya
N
Suzuki
Kyoko
K
Yamada
Yoshiteru
Y
Kosaka
Kenji
K
D014150:Antipsychotic Agents / Q000627:therapeutic use; D044466:Asian People; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D007564:Japan; D009459:Neuroleptic Malignant Syndrome / Q000235:genetics*; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D017448:Receptors, Dopamine D2 / Q000235:genetics*; D012559:Schizophrenia / Q000188:drug therapy / Q000235:genetics; D019914:Taq Polymerase
D014150:Antipsychotic Agents; D017448:Receptors, Dopamine D2; D019914:Taq Polymerase